Drugs / GST-HG171
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT06087055 | May → Jun 2023 | — | Fujian Akeylink Biotechnology Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT06084507 | May 2023 | COVID-19 | Fujian Akeylink Biotechnology Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT06106113 | Dec 2022 → Feb 2023 | pneumonia | Fujian Akeylink Biotechnology Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05668897 | Oct → Dec 2022 | COVID-19 | Fujian Akeylink Biotechnology Co., Ltd. | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT05656443 | Dec 2022 → May 2023 | pneumonia | Fujian Akeylink Biotechnology Co., Ltd. | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06106126 | Feb 2023 → Feb 2024 | pneumonia | Fujian Akeylink Biotechnology Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GST-HG171 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06106113 ↗ |
| Known as | atilotrelvir | “GST-HG171 (also known as atilotrelvir) is a novel, orally administered 3CL protease inhibitor approved in China for treating mild-to-moderate COVID-19.” PMID 42112804 ↗ May 2026 |
| Action | Inhibit | “3C like protease inhibitor” PMID 38618202 ↗ Apr 2024 |
| Modality | Small molecule | “orally bioavailable small-molecule 3C like protease inhibitor” PMID 38618202 ↗ Apr 2024 |
| Route | Oral | “orally administered GST-HG171 plus Ritonavir” PMID 38618202 ↗ Apr 2024 |